1-20 of 64
Saad Usmani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Anthony M. Cirrincione, Alexandra M. Poos, Bachisio Ziccheddu, Marcella Kaddoura, Marc-Andrea Bärtsch, Kylee Maclachlan, Monika Chojnacka, Benjamin Diamond, Lukas John, Philipp Reichert, Stefanie Huhn, Patrick Blaney, Dylan Gagler, Karsten Rippe, Yanming Zhang, Ahmet Dogan, Alexander M. Lesokhin, Faith Davies, Hartmut Goldschmidt, Roland Fenk, Katja C. Weisel, Elias K. Mai, Neha Korde, Gareth J. Morgan, Saad Usmani, Ola Landgren, Marc S. Raab, Niels Weinhold, Francesco Maura
Journal: Blood
Blood (2024) 144 (7): 771–783.
https://doi.org/10.1182/blood.2024024299
Published: 2024
Includes: Supplemental data
Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Benjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, Justin Taylor, Eileen Boyle, Juan Arango Ossa, Jacob Jahn, Maurizio Affer, Tulasigeri M. Totiger, David Coffey, Namrata Chandhok, Justin Watts, Luisa Cimmino, Sydney X. Lu, Niccolò Bolli, Kelly Bolton, Heather Landau, Jae H. Park, Karuna Ganesh, Andrew McPherson, Mikkael A. Sekeres, Alexander Lesokhin, David J. Chung, Yanming Zhang, Caleb Ho, Mikhail Roshal, Jeffrey Tyner, Stephen Nimer, Elli Papaemmanuil, Saad Usmani, Gareth Morgan, Ola Landgren, Francesco Maura
Journal: Blood
Blood (2023) 141 (19): 2359–2371.
https://doi.org/10.1182/blood.2022018244
Published: 2023
Includes: Supplemental data
Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Rebecca Silbermann, Jacob Laubach, Jonathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Katharine S. Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 1146–1149.
https://doi.org/10.1182/blood-2022-162313
Published: 2022
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Diana Cortes-Selva, Tineke Casneuf, Deeksha Vishwamitra, Sarah Stein, Tatiana Perova, Sheri Skerget, Elena Ramos, Laure van Steenbergen, Dries De Maeyer, Rengasamy Boominathan, Onsay Lau, Cuc Davis, Arnob Banerjee, Tara Stephenson, Clarissa M. Uhlar, Rachel Kobos, Jenna D. Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Usmani, Nizar Jacques Bahlis, Niels WCJ Van De Donk, Raluca Verona
Journal: Blood
Blood (2022) 140 (Supplement 1): 241–243.
https://doi.org/10.1182/blood-2022-162709
Published: 2022
Journal Articles

Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients

Neha Korde, Benjamin Diamond, Miranda Burge, Hani Hassoun, Heather Landau, Malin Hultcrantz, Sham Mailankody, Kylee H Maclachlan, Urvi A Shah, Andriy Derkach, Saad Usmani, Ola Landgren, Alexander Lesokhin
Journal: Blood
Blood (2022) 140 (Supplement 1): 2397–2398.
https://doi.org/10.1182/blood-2022-169937
Published: 2022
Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Nicole Watts, Barry Paul, Saurabh Chhabra, Neha Korde, Xhevahire Begic, David M Foureau, David J. Chung, Mauricio Pineda-Roman, Brinda Koya, Cindy Varga, Jing Ai, Natonya Daniels, Sarah Norek, Sara A Sutton, Michelle B Anderson, Ashley N Jewell, Paul W Eldridge, Donna Acampora, James T Symanowski, Luciano J. Costa, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 4393–4395.
https://doi.org/10.1182/blood-2022-160071
Published: 2022
Journal Articles

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Xin Miao, Liviawati S. Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yuki Iwaki, Rachel Kobos, Tara Stephenson, Kristy Kemmerer, Clarissa M. Uhlar, Arnob Banerjee, Jenna D. Goldberg, Danielle Trancucci, Raluca Verona, Lixia Pei, Yaming Su, Daniele Ouellet, Alfred L. Garfall, Amrita Y. Krishnan, Saad Usmani, Suzette Girgis, Honghui Zhou
Journal: Blood
Blood (2022) 140 (Supplement 1): 4382–4383.
https://doi.org/10.1182/blood-2022-162859
Published: 2022
Journal Articles

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Usmani, Krina Patel, Parameswaran Hari, Jesus Berdeja, Melissa Alsina, Ravi Vij, Noopur Raje, Xavier Leleu, Madhav Dhodapkar, Ran Reshef, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Chiara Greggio, Linda Favre-Kontula, Lars Sternas, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 875–877.
https://doi.org/10.1182/blood-2022-162469
Published: 2022
Journal Articles

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Patrick Blaney, Eileen M Boyle, Kylee H Maclachlan, Louis S. Williams, Dylan Gagler, Parvathi Sudha, Alexandra M Poos, Yubao Wang, Hussein Ghamlouch, Avital Tenenbaum, Ariel Siegel, Xiaoyi Chen, Gaurav Varma, David Kaminetzsky, Marc Braunstein, David Coffey, Benjamin Diamond, Bachisio Ziccheddu, Dickran Kazandjian, Urvi A Shah, Elizabeth E. Brown, Elisabet E. Manasanch, Alexander M Lesokhin, Niels Weinhold, Brian A. Walker, Saad Usmani, Ola Landgren, Faith E Davies, Francesco Maura, Gareth J. Morgan
Journal: Blood
Blood (2022) 140 (Supplement 1): 430–432.
https://doi.org/10.1182/blood-2022-167390
Published: 2022
Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C. Munshi, Bruno Paiva, Thomas Martin, Saad Usmani, Yi Lin, Jordan M. Schecter, Carolyn C. Jackson, Deepu Madduri, Enrique Zudaire, Tzu-min Yeh, J. Blake Bartlett, Lida Pacaud, Muhammad Akram, Dong Geng, Sundar Jagannath, Adam D. Cohen, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4652–4654.
https://doi.org/10.1182/blood-2022-159141
Published: 2022
Journal Articles

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience

Malin Hultcrantz, Andriy Derkach, Hani Hassoun, Neha Korde, Kylee H Maclachlan, Sham Mailankody, Dhwani Patel, Urvi A Shah, Carlyn Tan, Theresia Akhlaghi, Issam S. Hamadeh, David J. Chung, Oscar B Lahoud, Heather Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Alexander M Lesokhin, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 7246–7248.
https://doi.org/10.1182/blood-2022-171077
Published: 2022
Journal Articles

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Francesco Maura, Arjun Raj Rajanna, Andriy Derkach, Bachisio Ziccheddu, Niels Weinhold, Kylee H Maclachlan, Benjamin Diamond, Faith E. Davies, Eileen Boyle, Brian A. Walker, Alexandra M Poos, Malin Hultcrantz, Ariosto Siqueira Silva, Oliver Hampton, Jamie Teer, Niccolò Bolli, Graham Jackson, Martin F. Kaiser, Charlotte Pawlyn, Gordon Cook, Dennis Verducci, Dickran Kazandjian, Frits van Rhee, Saad Usmani, Ken H. Shain, Marc S Raab, Gareth J. Morgan, Ola Landgren
Journal: Blood
Blood (2022) 140 (Supplement 1): 1561–1563.
https://doi.org/10.1182/blood-2022-160215
Published: 2022
Journal Articles

A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea

Malin Hultcrantz, Hani Hassoun, Neha Korde, Sham Mailankody, Tala Shekarkhand, Miranda Burge, Kylee H Maclachlan, Dhwani Patel, Urvi A Shah, David J. Chung, Michael Scordo, Kelly Barnett, Jenna Blaslov, Meghan Salcedo, Julia Caple, Linh Tran, Selena Hamid, Oscar B Lahoud, Heather Landau, Gunjan L. Shah, Sergio A Giralt, Andriy Derkach, Carlyn Tan, Cody Peer, William D. Figg, Sr., Saad Usmani, Ola Landgren, Alexander M Lesokhin
Journal: Blood
Blood (2022) 140 (Supplement 1): 4454–4456.
https://doi.org/10.1182/blood-2022-164851
Published: 2022
Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 4440–4441.
https://doi.org/10.1182/blood-2022-160204
Published: 2022
Journal Articles

Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival

Srinivasa Reddy Sanikommu, Shebli Atrash, Myra Robinson, Nury M. Steuerwald, Kristen Cassetta, Hsih-Te Yang, Saad Usmani, Edward A. Copelan, Belinda R. Avalos, Lawrence J. Druhan
Journal: Blood
Blood (2022) 140 (Supplement 1): 11416–11417.
https://doi.org/10.1182/blood-2022-170887
Published: 2022
Journal Articles

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Bachisio Ziccheddu, Benjamin Diamond, Kylee H Maclachlan, Justin Taylor, Eileen M Boyle, Juan E. Arango Ossa, Jahn Jacob, Maurizio Affer, Tulasigeri M Totiger, David Coffey, Justin Watts, Sydney X. Lu, Niccolo Bolli, Kelly L Bolton, Jae H Park, Heather Landau, Karuna Ganesh, Andrew McPherson, Mikkael A. Sekeres, Alexander M Lesokhin, David J. Chung, Yanming Zhang, Caleb Ho, Mikhail Roshal, Jeffrey W. Tyner, Stephen D Nimer, Elli Papaemmanuil, Saad Usmani, Gareth J. Morgan, Ola Landgren, Francesco Maura
Journal: Blood
Blood (2022) 140 (Supplement 1): 2088–2090.
https://doi.org/10.1182/blood-2022-158992
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Ajai Chari, Jonathan L. Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 7278–7281.
https://doi.org/10.1182/blood-2022-162339
Published: 2022
Journal Articles

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Francesco Maura, Eileen Boyle, David Coffey, Kylee H Maclachlan, Benjamin Diamond, Patrick Blaney, Dylan Gagler, Bachisio Ziccheddu, Hussein Ghamlouch, Yubao Wang, James E. Hoffman, Dickran Kazandjian, Hani Hassoun, Emily Guzman, Sham Mailankody, Urvi A Shah, Carlyn Tan, Malin Hultcrantz, Michael Scordo, Gunjan L. Shah, Heather Landau, David J. Chung, Sergio A. Giralt, Yanming Zhang, Ahmet Dogan, Alexander M Lesokhin, Dennis Verducci, Faith E. Davies, Saad Usmani, Neha Korde, Gareth J. Morgan, Ola Landgren
Journal: Blood
Blood (2022) 140 (Supplement 1): 1137–1139.
https://doi.org/10.1182/blood-2022-160308
Published: 2022